Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

1.

Whole cell ELISA for detection of tumor antigen expression in tumor samples.

Erdile LF, Smith D, Berd D.

J Immunol Methods. 2001 Dec 1;258(1-2):47-53.

PMID:
11684122
[PubMed - indexed for MEDLINE]
2.

Expression of melanoma-associated antigens in short-term melanoma cultures detected by RT-PCR and subsequent ELISA.

Hofbauer GF, Dummer R, Laine E, Burg G.

Arch Dermatol Res. 1998 Aug;290(8):458-61. No abstract available.

PMID:
9763311
[PubMed - indexed for MEDLINE]
3.

Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.

Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA.

J Immunother Emphasis Tumor Immunol. 1996 May;19(3):192-205.

PMID:
8811494
[PubMed - indexed for MEDLINE]
4.

Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases.

Mocellin S, Fetsch P, Abati A, Phan GQ, Wang E, Provenzano M, Stroncek D, Rosenberg SA, Marincola FM.

J Immunother. 2001 Nov-Dec;24(6):447-58.

PMID:
11759068
[PubMed - indexed for MEDLINE]
5.

Production and characterization of monoclonal antibodies against a human ovarian teratocarcinoma cell line.

Lemieux P, Pagé M.

Anticancer Res. 1994 Nov-Dec;14(6B):2709-15.

PMID:
7872706
[PubMed - indexed for MEDLINE]
6.

Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy.

Bredenbeck A, Losch FO, Sharav T, Eichler-Mertens M, Filter M, Givehchi A, Sterry W, Wrede P, Walden P.

J Immunol. 2005 Jun 1;174(11):6716-24.

PMID:
15905511
[PubMed - indexed for MEDLINE]
Free Article
7.

Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines.

Astsaturov I, Petrella T, Bagriacik EU, de Benedette M, Uger R, Lumber G, Berinstein N, Elias I, Iscoe N, Hammond C, Hamilton P, Spaner DE.

Clin Cancer Res. 2003 Oct 1;9(12):4347-55.

PMID:
14555505
[PubMed - indexed for MEDLINE]
Free Article
8.

Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than in primary melanoma lesions.

Geertsen RC, Hofbauer GF, Yue FY, Manolio S, Burg G, Dummer R.

J Invest Dermatol. 1998 Sep;111(3):497-502.

PMID:
9740247
[PubMed - indexed for MEDLINE]
9.

Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy.

Wagner SN, Wagner C, Schultewolter T, Goos M.

Cancer Immunol Immunother. 1997 Jun;44(4):239-47.

PMID:
9222283
[PubMed - indexed for MEDLINE]
10.

Melanoma antigen expression in serial fine-needle aspiration samples in patients with metastatic malignant melanoma participating in immunotherapy clinical trials: a preliminary look.

Fetsch PA, Steinberg SM, Riker AI, Marincola FM, Abati A.

Cancer. 2001 Dec 25;93(6):409-14.

PMID:
11748581
[PubMed - indexed for MEDLINE]
11.

Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.

Akiyama Y, Maruyama K, Tai S, Takikawa M, Ohshita C, Yamamoto A, Yamazaki N, Kiyohara Y, Yamaguchi K.

Int J Oncol. 2008 Sep;33(3):433-41.

PMID:
18695871
[PubMed - indexed for MEDLINE]
12.

Quantitation of the density of cell surface carbohydrate antigens on cancer cells with a sensitive cell-suspension ELISA.

Ravindranath MH, Bauer PM, Cornillez-Ty C, Garcia J, Morton DL.

J Immunol Methods. 1996 Oct 16;197(1-2):51-67.

PMID:
8890894
[PubMed - indexed for MEDLINE]
13.

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.

Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, Lee PP.

Cancer. 2003 Jan 1;97(1):186-200.

PMID:
12491520
[PubMed - indexed for MEDLINE]
Free Article
14.

gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.

Walker EB, Haley D, Miller W, Floyd K, Wisner KP, Sanjuan N, Maecker H, Romero P, Hu HM, Alvord WG, Smith JW 2nd, Fox BA, Urba WJ.

Clin Cancer Res. 2004 Jan 15;10(2):668-80.

PMID:
14760090
[PubMed - indexed for MEDLINE]
Free Article
15.

Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.

Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA.

Cancer J Sci Am. 1998 Sep-Oct;4(5):316-23.

PMID:
9815296
[PubMed - indexed for MEDLINE]
16.

Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.

Cormier JN, Abati A, Fetsch P, Hijazi YM, Rosenberg SA, Marincola FM, Topalian SL.

J Immunother. 1998 Jan;21(1):27-31.

PMID:
9456433
[PubMed - indexed for MEDLINE]
17.

Tumor-associated antigens recognized by human monoclonal antibodies.

Chang HR, Koda K, McKnight ME, Glassy MC.

Ann Surg Oncol. 1994 May;1(3):213-21.

PMID:
7842291
[PubMed - indexed for MEDLINE]
18.

Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100.

Spaner DE, Astsaturov I, Vogel T, Petrella T, Elias I, Burdett-Radoux S, Verma S, Iscoe N, Hamilton P, Berinstein NL.

Cancer. 2006 Feb 15;106(4):890-9.

PMID:
16404742
[PubMed - indexed for MEDLINE]
Free Article
19.

Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.

Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R, Morton DL, Hoon DS.

Am J Pathol. 1997 Jun;150(6):2143-52.

PMID:
9176405
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells.

Jantscheff P, Spagnoli G, Zajac P, Rochlitz CF.

Cancer Immunol Immunother. 2002 Sep;51(7):367-75. Epub 2002 Jun 25.

PMID:
12192536
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk